1. Market Research
  2. > Bacteremia - Pipeline Review, H1 2013

Bacteremia - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 47 pages

Bacteremia - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Bacteremia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bacteremia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacteremia. Bacteremia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Bacteremia.
- A review of the Bacteremia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bacteremia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Bacteremia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bacteremia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Bacteremia - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bacteremia Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Bacteremia 7
Bacteremia Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
Bacteremia Therapeutics - Products under Development by Companies 13
Nabriva Therapeutics AG 14
Sinovac Biotech Ltd. 15
Trius Therapeutics, Inc. 16
Max Planck Innovation GmbH 17
Bacteremia - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
BC-3781 - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
tedizolid phosphate - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Pneumococcal Polysaccharides Vaccine - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Drugs For Human Septicaemia - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
MAb Against S aureus - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Human Neutrophil Alpha Defensin-1 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Human Neutrophil Alpha Defensin-2 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Human Neutrophil Alpha Defensin-3 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
ceftriaxone sodium CR - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Bacteremia Therapeutics - Drug Profile Updates 33
Bacteremia Therapeutics - Discontinued Products 39
Bacteremia Therapeutics - Dormant Products 40
Bacteremia - Product Development Milestones 41
Featured News and Press Releases 41
Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate Cubicin At ICAAC 2012 41
Apr 11, 2011: Trius Announces Patent Term Extension For Torezolid Phosphate 41
Apr 04, 2011: Cubist Pharma Settles CUBICIN Patent Litigation With Teva 42
Dec 01, 2010: Cubist Receives FDA Approval For Two-Minute IV Injection Of CUBICIN 42
Jul 13, 2010: Cubist Announces Objectives Met in Phase 2 Safety Study of CUBICIN in Prosthetic Joint Infections 43
May 12, 2010: Markman Hearing in CUBICIN Patent Litigation Rescheduled to June 9, 2010 43
Dec 11, 2009: Trial Date Set for CUBICIN Patent Litigation 44
Jan 05, 2009: Cubist Pharmaceuticals, the Developer of CUBICIN, Announces Submission of 2 INDs Targeting Serious Infections Caused by MDR Gram-negative Pathogens and by Clostridium difficile 44
Oct 21, 2008: CUBICIN Outcomes Registry and Experience (CORE) Marks Milestone 44
Oct 16, 2008: Cubist Pharmaceuticals Q3 2008 Revenues up 41%; Net Income up 39%: Total Revenues $112.4 Million; CUBICIN Net Product Revenues $110.6 Million 44
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables


Number of Products Under Development for Bacteremia, H1 2013 7
Products under Development for Bacteremia - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Comparative Analysis by Mid Clinical Stage Development, H1 2013 10
Comparative Analysis by Early Clinical Stage Development, H1 2013 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 12
Products under Development by Companies, H1 2013 13
Nabriva Therapeutics AG, H1 2013 14
Sinovac Biotech Ltd., H1 2013 15
Trius Therapeutics, Inc., H1 2013 16
Max Planck Innovation GmbH, H1 2013 17
Assessment by Monotherapy Products, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 22
Bacteremia Therapeutics - Drug Profile Updates 33
Bacteremia Therapeutics - Discontinued Products 39
Bacteremia Therapeutics - Dormant Products 40

List of Figures


Number of Products under Development for Bacteremia, H1 2013 7
Products under Development for Bacteremia - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Mid Clinical Stage Products, H1 2013 10
Early Clinical Stage Products, H1 2013 11
Discovery and Pre-Clinical Stage Products, H1 2013 12
Assessment by Monotherapy Products, H1 2013 18
Assessment by Route of Administration, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Molecule Type, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.